^
    Back
    Association details:
    Biomarker:NOS2 underexpression
    Cancer:Estrogen Receptor Positive Breast Cancer
    Drug:tamoxifen (Estrogen receptor antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Lab Invest
    Title:

    Nitric oxide-targeted therapy inhibits stemness and increases the efficacy of tamoxifen in estrogen receptor-positive breast cancer cells

    Published date:
    12/01/2020
    Excerpt:
    Furthermore, low NOS2 expression was significantly associated with a higher metastasis-free survival in ER+ breast cancer patients treated with tamoxifen.
    DOI:
    10.1038/s41374-020-00507-z